Gland Pharma’s Board of Directors will meet on Wednesday, January 28, 2026, to review and approve the unaudited standalone and consolidated financial results for the quarter and nine months ending December 31, 2025. The trading window, previously closed from December 27, 2025, will reopen on Saturday, January 31, 2026. An Investor/Analyst call is scheduled for January 28, 2026, at 18:30 Hrs (IST).
Board Meeting Announcement
The Board of Directors of Gland Pharma Limited is scheduled to convene a meeting on Wednesday, January 28, 2026. The primary agenda is to consider and approve the Unaudited Standalone and Consolidated Financial Results of the company.
Financial Results Review
The board will specifically focus on the financial performance for the quarter and nine months that concluded on December 31, 2025.
Trading Window Update
The company confirms that the trading window, which was previously closed starting Saturday, December 27, 2025, will be reopened for trading activities on Saturday, January 31, 2026.
Investor/Analyst Call
An Investor/Analyst call is scheduled to take place on Wednesday, January 28, 2026, at 18:30 Hrs (IST). Additional details regarding the call will be shared with the stock exchanges and made available on the company’s official website (www.glandpharma.com).
Source: BSE
